PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma

BACKGROUND: Few tissue biomarkers exist to date that could enrich patient with cancer populations to benefit from immune checkpoint blockade by programmed cell death protein 1/ligand-1 (PD-/L-1) inhibitors. PD-L1 expression has value in this context in some tumor types but is an imperfect predictor...

Descripción completa

Detalles Bibliográficos
Autores principales: Homicsko, Krisztian, Zygoura, Panagiota, Norkin, Maxim, Tissot, Stephanie, Shakarishvili, Nicholas, Popat, Sanjay, Curioni-Fontecedro, Alessandra, O'Brien, Mary, Pope, Anthony, Shah, Riyaz, Fisher, Patricia, Spicer, James, Roy, Amy, Gilligan, David, Rusakiewicz, Sylvie, Fortis, Ekaterina, Marti, Nesa, Kammler, Roswitha, Finn, Stephen P, Coukos, Georges, Dafni, Urania, Peters, Solange, Stahel, Rolf A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603330/
https://www.ncbi.nlm.nih.gov/pubmed/37880184
http://dx.doi.org/10.1136/jitc-2023-007585

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603330/
https://www.ncbi.nlm.nih.gov/pubmed/37880184
http://dx.doi.org/10.1136/jitc-2023-007585

Ejemplares similares